Introduction {#S1}
============

The infrapatellar fat pad (IFP), also known as Hoffa's fat pad, is a cylinder-like piece of adipose tissue that sits posterior to the patella and fills the anterior knee compartment ([@B47]). Though the function of the IFP has not yet been fully defined, studies have shown that the IFP plays an important biomechanical role within the knee ([@B18]; [@B63]). In addition, recent evidence has shown that the IFP in concert with the synovium participates in the pathogenesis and progression of various pathologies within the knee joint such as osteoarthritis (KOA) ([@B16]; [@B152]; [@B159]; [@B111]; [@B55]; [@B54]; [@B124]), given that these structures serve as sites of immune cell infiltration and origin of pro-inflammatory (*e.g.*, IFNγ, TNFα and IL1β) and articular cartilage degradative (*e.g.*, MMPs) molecules ([@B20]; [@B87]; [@B110]). On the other hand, they may be related with repair attempts after injury, due to the presence of mesenchymal stem/stromal cells (MSCs) within both the IFP (IFP-MSC) ([@B64]; [@B167]; [@B102]) and the synovium (sMSC) ([@B132]; [@B168]) exhibiting disease-modifying capacities ([@B28]; [@B162]; [@B173]; [@B62]). Consequently, the IFP and synovium engage not only in amplifying local pathological responses, but also act as a reservoir of disease-modifying cellular products, promoting them as potential novel targets in joint disease ([@B5]).

IFP-MSCs have generated increased interest in recent literature due to their easy accessibility compared to other stem cell sources such as bone marrow and adipose tissue (AT), while displaying similar multipotency, growth potential, and immunomodulatory abilities ([@B164]). Their relative ease of isolation compared to bone marrow aspiration (thus removing the potential surgical complications seen with aspiration) have made them a popular resource for experimentation and regenerative medicine ([@B175]; [@B131]; [@B157]). However, because of its relatively newfound MSC population, current literature has re-focused on updating the knowledge of IFP anatomy, function, and most importantly its cellular composition beyond MSC. This has not only led to extensive investment in the IFP's potential for regenerative medicine in Orthopedics, but also the role the IFP may play in certain pathological processes including KOA. For example, more established theories believe that the IFP communicates with the joint via the synovium and may play a role in cartilage and/or bone regeneration via the secretion of adipose tissue derived growth factors ([@B84]). However, a shift in our understanding of the IFP anatomy and pathophysiology demonstrates not only that the IFP and the synovium constitute one structural and functional unit ([@B117]), but that IFP-MSCs can regulate resident immune cell infiltration and resident macrophages thus acting as local immunomodulatory players.

Therefore, the goal of this review is to outline the latest developments of the IFP/synovium complex as a tissue that actively participates in joint homeostasis and disease, while harboring cellular elements that can be harnessed for therapeutic cell-based therapy protocols. In addition, updates regarding recent discoveries in anatomy, cellular composition, function, isolation and harvest, imaging, role in certain pathologies of the knee (most importantly modulation of inflammation in the joint), current therapeutic uses, and future perspectives and goals for IFP use will be discussed.

Structure and Function of the IPF/Synovium Complex {#S2}
==================================================

Anatomy {#S2.SS1}
-------

The IFP is located deep to the patella and occupies the space between the patellar tendon, femoral condyle, and tibial plateau. It attaches to the lower border of the patella, the intercondylar notch within the femur via the ligamentum mucosum, the periosteum of the tibia, and the anterior horn of both menisci ([@B63]). Of note, recent study of IFP anatomy has demonstrated previously undiscovered attachments to the deep quadriceps muscle, which may assist with IFP motion during walking ([@B180]).

Although the IFP is intracapsular, it remains extrasynovial despite its constant contact with the synovium ([@B32]). Increasing evidence has demonstrated that the IFP develops as an outgrowth of the synovial tissue with regard to structure and functionality, which suggests extensive communication between the IFP and the synovium and joint capsule ([Figure 1](#F1){ref-type="fig"}) ([@B80]). Furthermore, [@B117] have concluded that the IFP and the synovium should be viewed as one anatomo-functional unit rather than two distinct structures that simply communicate with one another. The authors justified this definition because recent anatomical studies demonstrated the insertion of infrapatellar and medial synovial plicae directly onto the IFP, which suggests that the IFP may not be extrasynovial, but rather an extension of the synovium outside of the joint capsule ([@B117]). Nevertheless, the intimate relationship between the synovium and IFP appears highly important in the release of growth factors and cytokines that help to regulate the molecular environment within the joint.

![Demonstration of the extensive molecular cross-talk and important cellular components between the IFP and the synovium within the joint capsule which are responsible for inflammation/fibrosis.](fbioe-08-00860-g001){#F1}

The extensive anastomotic vascular network near the IFP involves a combination of the superior and inferior geniculate arteries, the latter which passes through the IFP before supplying the patella. This matrix helps support and promote IFP-MSC proliferation, especially during injury and inflammation. It has also been hypothesized that this network is sufficient to protect the IFP during extensive surgical or arthroscopic procedures that lead to significant manipulation of the structure itself ([@B99]).

Innervation to the IFP is just as extensive as its vasculature and typically traverses the same course across the entire tissue. Previous studies have confirmed that posterior articular branches from the tibial, saphenous, recurrent peroneal, and common peroneal nerve provide most of the innervation, however Gardner et al. recently described branches arising from the saphenous and obturator nerves as well ([@B61]; [@B91]). This collective peripheral sensory nociceptive innervation pattern (dense in parts of the IFP and synovium) is mediated by nerve fibers equipped with the neurotransmitter Substance P which runs separately but in parallel to sympathetic fibers and it is implicated in knee pain transmission. Additionally, within the IFP tyrosine hydroxylase (TH)-positive sympathetic fibers modulate nociception/pain signaling in sympathetic neurons, through interacting with Substance P-positive fibers ([@B47]; [@B24]).

Cellular Composition and Molecular Mediators {#S2.SS2}
--------------------------------------------

### Infrapatellar Fat Pad {#S2.SS2.SSS1}

The most prevalent cell is the adipocyte, which is not only responsible for the IFP's metabolism, but also endocrine and paracrine functions within the knee joint ([@B33]; [@B46]). Importantly, adipose cells secrete cytokines, interferons, adipokines, and growth factors, all of which exerting local signaling effects on articular cartilage and synovial cells ([@B32]).

As shown in [Figure 1](#F1){ref-type="fig"}, other important cellular components of the IFP include fibroblasts, responsible for the production of extracellular matrix, and in less quantities resident monocytes, mast cells, lymphocytes, and perhaps most importantly macrophages ([@B42]; [@B15]; [@B102]). [@B10] have demonstrated that macrophages not only permanently reside within the IFP, but lie without phenotypic polarization as either classical M1 or alternative M2 variants until conditions promote their activation and subsequent conversion, such as inflammation.

Resident IFP macrophages are activated by a variety of interleukins and interferons secreted from other resident and infiltrating immune cells and adipose cells within the IFP. When converted to M1 macrophages, the IFP begins secreting vast amounts of pro-inflammatory cytokines, catabolic factors, and adipokines, and with prolonged periods of time, the IFP can also release pro-fibrotic mediators such as CTGF that may contribute to KOA progression ([Figure 2](#F2){ref-type="fig"}) ([@B32]). This occurs due to tight molecular crosstalk between synovial, IFP, and systemic inflammatory mediators. Consequently, these macrophages are now the target of studies assessing their release of pro-inflammatory molecular mediators ([@B102]). On the other hand, also shown in [Figure 2](#F2){ref-type="fig"}, alternatively differentiated M2 macrophages exert anti-inflammatory effects, serving as counterbalance to their M1 cohorts by suppressing their proliferation and inflammatory signaling.

![Schematic showing the intricate balance between M1 and M2 macrophages within the IFP and synovium. Differentiated M2 macrophages exhibit anti-inflammatory effects and preserve the health of the joint, whereas an imbalance favoring M1 macrophages promotes the IFP's secretion of pro-inflammatory cytokines and catabolic factors that are seen within an inflamed/fibrotic knee.](fbioe-08-00860-g002){#F2}

Finally, the IFP harbors a population of MSC (IFP-MSC), which will be discussed in detail later (see section "Synovium-Derived MSC") as a potential therapeutic tool for cell-based therapy protocols.

### Synovium {#S2.SS2.SSS2}

Within the intimal synovial lining reside predominantly two synovial cell types: type A (Macrophage-Like synoviocytes -- MLS) and type B (Fibroblast-Like-Synoviocytes -- FLS) ([@B172]). The type B synoviocytes, thought to be descendants of cells of mesodermal origin, are far more abundant and display typical fibroblast markers such as surface marker Thy-1 (CD90) and integrins like ICAM1 while secreting specialized matrix constituents including hyaluronan and Type IV and V collagens ([@B148]; [@B172]). Thus, it can be argued that type B synoviocytes more so than type A counterparts are responsible for maintenance of synovial homeostasis.

Type B synoviocytes are subject to cytokine and growth factor regulation, which can dictate a pro or anti-inflammatory state depending on which factors are expressed in the surrounding synovial environment ([@B140]). In a chronic inflammatory state, these cells primarily act in a pro-inflammatory role. For example, in patients with rheumatoid arthritis, fibroblasts have been shown to respond to and secrete a combination of TNF-alpha, IL-1, IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF), while expressing a multitude of toll-like receptors in order to amplify T-Cell response to TLR activation ([@B141]). In regard to patients with OA, type B synoviocytes are particularly sensitive to TLR-2, TLR-3, and TLR-4 ligands due to the active expression of CD14, a co-receptor for TLRs ([@B136]). Type B synoviocytes also secrete a multitude of chemoattractants, including CCL2, CCL5, CCL8, CXCL5, and CXCL10, designed to attract monocytes and macrophages, both resident and peripheral in nature ([@B11]). Finally, upon stimulation of TLR-3, these synoviocytes produce large quantities of IL6, B-Cell Activating Factor and proliferation-inducing ligand ([@B121]), promoting the maturation, survival, and antibody production by B cells ([@B19]). These findings suggest that type B synoviocytes, though non-immune in nature, play a key role in autoimmune and OA disease development due to their inflammatory properties.

Type B synoviocytes can also produce a wide variety of anti-inflammatory factors such as TGF-beta, Type 1 interferons, VEG-F, indoleamine 2,3-dioxygenase (IDO enzyme), and certain prostaglandins, though some of these factors depending on concentration and exposure time may also be pro-inflammatory ([@B172]). However, the ability to harness the anti-inflammatory properties of these cells remains unknown. The recent proposition that type B synoviocytes may also contain multiple subtypes within the synovial lining which determine their secretory properties provides a future avenue for studies attempting to fully elucidate the role of these cells in arthritis development or modulation ([@B60]).

On the other hand, type A synoviocytes are far less known due to the limited number of these cells *in vivo* and their poor proliferative potential *in vitro*. They constitute resident macrophages, derived from both embryonic hematopoietic precursors and from bone marrow, although their definitive origin is still elusive ([@B172]). These resident macrophages need to be discriminated from monocytes/macrophages that extravasate into the synovium from peripheral circulation after injury or in disease. Nevertheless, it has been established that they have pro-inflammatory tendencies while exhibiting an intimate crosstalk with type B synoviocytes, especially in disease ([@B172], [@B171]). Type A synoviocytes secrete soluble CD14, IL-1β, and TNFα, further potentiating the pro-inflammatory properties of type B synoviocytes and CD4 T helper cells. They also induce monocyte/macrophage-derived osteoclast activity via RANK-L secretion resulting in enhanced bone resorption ([@B183]). It is interesting to note given the above pro-inflammatory properties that the presence and activity levels of these tissue-resident macrophages significantly correlates with advanced stages of OA and poorer clinical outcome scores ([@B105]; [@B71]).

Similar to the IFP, the synovium contains a small population of cells compatible with MSC (sMSC), which will be discussed in detail in section "MSC-Induced Immunomodulation: Focus on Macrophage Polarization."

### IFP/Synovium Molecular Interactions {#S2.SS2.SSS3}

Beyond the proximity the IFP and synovium share, there are molecular interactions between both components that support their view as a single anatomical and functional unit. For instance, both IFP and adjacent synovium experience similar structural effects in KOA, including increased inflammatory infiltration, vascularization, and thickness ([@B54]). The IFP has been shown to release prostaglandin F2a (PGF2α), IL-6, IL-8, and TNFα, inducing a profibrotic effect on the synovial membrane ([@B13]; [@B51]). Specifically, [@B13] cultured human fibroblast -like synoviocytes (type B) obtained from OA patients in conditioned medium derived from IFP tissue with and without inhibitors of TGFβ/activin receptor-like kinase 5 or PGF2α for 4 days *in vitro*. IFP derived conditioned medium not only increased the migration and proliferation of synoviocytes but also resulted in profibrotic changes including Collagen production and *PLOD2* gene expression upregulation. Collagen production in synoviocytes was directly associated with secreted PGF2α levels in IFP derived conditioned medium. On the other hand, as the IFP is mainly composed of adipocytes, it results as a major source of various adipocyte-derived inflammatory mediators including lipids. Previous studies indicated that IFP-derived adipocytes, via secreted lipids, are able to modulate infiltrating macrophages and CD4^+^ T cells into the OA synovium ([@B82]; [@B94]). In adipocyte-derived conditioned medium obtained from IFP, [@B82] identified free fatty acids that enhance CD4^+^ T cell proliferation and their capacity to produce IFN-γ. Additionally, free fatty acids secreted from IFP adipocytes can reduce the secretion of IL-12p40 cytokine by macrophages ([@B94]). According to previous studies (reviewed in [@B34]), IL-12p40 is a chemoattractant molecule for macrophages, and which promotes inflammation and fibrosis. Furthermore, [@B134] identified distinct fatty acid signature for IFP in OA and rheumatoid arthritis (RA) patients. Compared to RA, OA patients have higher total n-6, 20:4n-6 and 22:6n-3 polyunsaturated fatty acids (PUFA), and higher product/precursor ratios of n-3 PUFA. In general, n-6 PUFA such as 20:4n-6 (arachidonic acid) are precursors to pro-inflammatory mediators, whereas n-3 PUFA such as 22:6n-3 (docosahexaenoic acid) have anti-inflammatory/anti-catabolic effects ([@B23]). Overall, the major alterations in OA and RA joints compared to control healthy knees are an increase in monounsaturated fatty acids and a simultaneous decrease in n-6 PUFA, effects that should be further investigated in future studies ([@B134]).

Just as IFP influences synovium, [@B30] demonstrated that extensive synovial proliferation and fibrosis led to marked loss of adipocytes within the IFP. Specifically, synovium secretion of pro-inflammatory cytokine IL-1β has been associated with catabolic effects in initiation and progression of OA. A previous study showed that exposure of IFP explants from OA patients to IL-1β *in vitro* result in secretion of large amounts of pro-inflammatory cytokines such as PTGS2, IL-1β, MCP-1, and IL-6. These effects can be partially ameliorated by a PPARα agonist ([@B31]). Thus, recent literature has not only demonstrated extensive communication between both the IFP and synovium, but that this communication can accelerate development and progression of KOA, as elaborated below.

IFP in the Pathogenesis of Knee OA -- Potential New Target for Therapy {#S3}
======================================================================

With the cellular composition of the IFP better elucidated and the occurrence of immune and inflammatory events within the IFP, its role in the pathophysiology of KOA is becoming the focus of multiple studies. For instance, [@B75] demonstrated that following ACL acute injury the IFP rapidly releases inflammatory cytokines that promote a sustained inflammatory response lasting for months. Consequently, various theories have emerged explaining the IFP's role in the regulation of local inflammatory cascades including adipocytes, and more recently resident macrophages as key targets (in the development of post-traumatic OA). We next explore the strengths and limitations of each prevailing theory.

IFP-Derived Adipocytes and Obesity Accelerate KOA Development {#S3.SS1}
-------------------------------------------------------------

As previously discussed, adipocytes are capable of secreting certain molecular markers and products capable of initiating a local inflammatory response. Given that obesity represents a chronic inflammatory state, many studies have focused on the role of adipocytes as contributors for accelerated development of KOA ([@B6]; [@B22]; [@B84]). Consistent with this theory, the discovery of IL-1β and other pro-inflammatory cytokine production, together with matrix metalloprotease expression within KOA cartilage by adipocytes, suggests that the IFP may be intimately linked to KOA ([@B32]; [@B40]; [@B14]). Furthermore, leptin and adiponectin have been shown to be primarily secreted by IFP adipocytes into synovial fluid, with a key role influencing cartilage and synovial metabolism ([@B49]; [@B170]). Therefore, the association of leptin to obesity and inflammation led to the belief that obesity itself plays a role in inducing IFP adipocyte inflammatory propagation and accelerated KOA progression ([@B80]). Leptin has been shown to promote production of articular cartilage proteoglycans and collagen while stimulating insulin-like growth factor-1 and other growth factors that subsequently enhance chondrocyte proliferation ([@B8], [@B9]). Lipid-mediated lipoxin A4, which can prevent cartilage degeneration in the knee, is also secreted by IFP adipocytes ([@B12]; [@B68]). Leptin facilitates the activation of immune cells, particularly M1 macrophages, via interferon release and nitric oxide production ([@B122]). Moreover, recent literature suggests that obese patients with OA have either no difference in the number of M1 macrophages within the IFP, or may even have an increased number of M2 macrophages, compared to that of lean patients ([@B41]). Lastly, even with M1 macrophages present within the IFP, the classic M1 macrophage mediated inflammation that usually occurs in abdominal adipose tissue as seen with obesity cannot be recapitulated, suggesting that IFP adipocytes are subject to distinct spatial-temporal metabolic regulation ([@B10]).

An alternative mechanism by which obesity may affect the IFP during the progression of KOA is through altered joint mechanics. [@B7] have shown that obese patients with KOA demonstrated significantly increased inflammatory signaling within the IFP measured by contrast-enhanced perfusion variables on MRI. [@B36] also demonstrated that patients with patellofemoral OA have a greater IFP volume on MRI compared to healthy knees. Because the IFP resides in a tight anatomical space, the authors suggested that increased IFP volume was an inducer of inflammation, leading to secretion of synovial inflammatory factors ([@B30]). Therefore, in this alternate hypothesis, adipocyte induced inflammation within the joint may be due to factors other than obesity ([@B93]). However, OA also occurs in non-weight bearing joints such as the hand, suggesting that the metabolic effects of obesity may play a greater role than altered joint mechanics ([@B116]; [@B184]; [@B17]).

Overall, though there is an established link between obesity and KOA, the explanation that the IFP propagates KOA development because of its primarily adipocyte-based composition remains controversial. Because the IFP has a distinct environment compared to abdominal adipose tissue, the role of this specific adipocyte population in KOA remains unclear and warrants continued investigation, as obesity related features seen in visceral adipose tissue are not present within the IFP of KOA patients ([@B41]).

Role of IFP/Synovium Resident Macrophages {#S3.SS2}
-----------------------------------------

Adipocytes are not the only cellular component with potential to induce or enhance inflammation locally. The IFP and synovium are populated by macrophages, historically viewed as cells that maintain tissue homeostasis with crucial roles in early and late phases of response to injury, while more recently associated with various pathologies ([@B29]; [@B125]; [@B70]). Macrophages have distinct origins resulting in significant heterogeneity, beyond the known M1 (classical pro-inflammatory) and M2 (alternative anti-inflammatory) polarization phenotypes ([@B70]; [@B144]; [@B181]). A special population of tissue resident macrophages derive from embryonic precursors, exhibit self-renewal, and replenish after injury independently from circulating bone marrow-derived Ly6C^High^ monocytes (Ly6C^High^ is a murine marker with no current human ortholog identified) ([@B38]; [@B67]; [@B69]; [@B186]). IFP and synovium show such resident populations with comparable immune cell profiles ([@B95]), also susceptible to polarize to M1 or M2 phenotypes depending on the status of the joint ([@B10]; [@B163]; [@B172]; [@B181]).

Resident M1 pro-inflammatory macrophages are theorized to be an important driver of the host low grade chronic inflammatory state ([@B125]; [@B88]). In fact, patients with KOA show a propensity for the M1 classical phenotype within the IFP/synovium complex, resulting in cytokine, interferon, and TNF-alpha secretion ([@B96]; [@B181]). Recent evidence suggests that activation of the mammalian target of rapamycin ([@B107]) pathway also plays a role in M1 macrophage polarization and progression of KOA in animal models ([@B57]). Nevertheless, the existence of resident macrophages within the IFP exhibiting an M1 phenotype independent of the presence of local inflammation confirms their potential participation as initiators of KOA ([@B181]). Thus, the propagation of KOA is not reliant solely on immune cell extravasation, but rather on resident cells from within the IFP/synovium complex, though the precise turning point that leads to KOA still remains unknown.

Immune Infiltration to the IFP/Synovium {#S3.SS3}
---------------------------------------

The aforementioned molecular markers that induce pro-inflammatory states do so in part by promoting extravasation of circulating immune cells into the IFP and synovium. The secretion of related prostaglandins, as well as IL-6 and IL-8 promote the extravasation of immune cells by attracting lymphocytes to the endothelium promoting their migration into the surrounding IFP and synovium ([@B153]). Substance P, a product of nociceptive nerve fibers that transmits pain signals while also modulates local inflammatory processes (*i.e.*, neurogenic inflammation), has also been shown to induce vasodilation of peripheral vessels, thus promoting the extravasation of immune cells from peripheral circulation into surrounding tissue ([@B32]).

[@B4] described the presence of peripheral CD8 T cells, macrophages, B cells, and mast cells within the IFP of patients with OA undergoing TKA. According to the authors, the infiltration of these cells trended with disease severity (patients with severe radiographic KOA had more CD8 T cell infiltration than patients with mild KOA), thereby leading the authors to conclude that the infiltration of circulating immune cells to the IFP and synovium contribute to disease progression and severity. In addition, [@B95] showed that peripheral CD4 T cells also infiltrate the IFP and synovium in a severely osteoarthritic population, and their presence correlated with pain scores (*R* = 0.53, *p* \< 0.01, *N* = 76 patients). Thus, pro-inflammatory cells within the IFP and synovium not only promote localized inflammation with resident immune cells, but also promote extravasation of circulating ones potentiating the inflammatory process that are associated with poorer clinical and radiographic outcomes.

Clinical Correlation: Imaging to Assess IFP Changes During OA Progression {#S3.SS4}
-------------------------------------------------------------------------

The IFP is best visualized on non-contrast magnetic resonance imaging (MRI) in the sagittal plane and intensity of signal alterations have recently been correlated with anterior knee pain and cartilage loss by Han et al. (OR 1.23, *p* \< 0.05, *N* = 374), supporting the link between changes in IFP and KOA development ([@B77]; [@B149]; [@B73]). Though non-contrast enhanced MRI is the gold standard, contrast-enhanced MRI imaging has recently been employed to show correlations between histological synovial infiltrate and hyperplasia and KOA progression (*R* = 0.63, *p* \< 0.001, *N* = 30) ([@B115]). [@B37] have shown that peri-patellar synovial thickness on non-contrast-enhanced MRI images could be the culprit for KOA related pain and not the changes in signal alterations within the IFP itself.

Interestingly, the size of the IFP may play an important role in KOA risk and symptom development and intensity. [@B143] demonstrated that decreased IFP volume in older women compared to men was significantly associated with increased total knee pain, pain at rest and during movement, and cartilage damage. However, the authors also found that total IFP maximal area appears to have a protective role for knee symptoms in older adult females, but not men. IFP signal intensity was later linked to size of IFP by [@B73], which provides support for continued use of non-contrast enhanced MRI as the gold standard. Recently, [@B59] reported changes in the morphometry (i.e., reduced volume, depth, and femoral and tibial arc lengths) and increase of the MRI hypointense signal in the IFP from patients with moderate and end-stage KOA compared to healthy controls. Despite contrasting results from various groups, the description of morphological changes in the IFP by MRI warrants continued investigation into how imaging may play a future in predicting KOA risk or progression.

IFP/Synovium as a Source of MSC for Cell Therapy {#S4}
================================================

IFP-MSC {#S4.SS1}
-------

In 1996 a pioneering study by [@B118] firstly described a type of fibroblastic cells possessing 'stem cell-like' characteristics in synovial tissue near the IFP. Those cells reside mostly in the perivascular space surrounding vessels of small caliber and involved in the fibronectin and laminin production. Recent studies have isolated and phenotypically characterized IFP-MSC positive for CD9, CD10, CD13, CD29, CD44, CD49e, CD59, CD73, CD90, CD105, CD106, CD146, CD166, NG2, and CXCR4 markers, while negative for CD34, CD56, CD200, CD271, 3G5, LepR and STRO-1 markers ([@B178]; [@B92]; [@B64]; [@B78]; [@B102]). IFP-MSC characteristically have low or no HLA-DR expression, yet a total absent expression of co-stimulatory molecules CD40, CD80, and CD86 ([@B64]; [@B104]). In a recent study, Hindle et al. identified two distinct IFP-MSC subpopulations within the IFP, characterized as pericytes (CD31^--^CD45^--^CD34^--^CD146^+^) and adventitial cells (CD31^--^CD45^--^CD34^+^CD146^--^), representing 3.8 and 21.2% of the IFP stromal vascular fraction, respectively ([@B78]).

In general, IFP-MSC have comparable proliferative potential to other MSC types ([@B48]; [@B86]). In comparative studies, IFP-MSC were reported to possess similar growth kinetics to bone marrow-derived MSC (BM-MSC) ([@B50]) and higher proliferation to donor-matched synovial fluid-MSC ([@B64]). However, in order to generate clinically relevant cell numbers, IFP-MSC growth rate can be accelerated by various *in vitro* culturing conditions such as human platelet lysate (hPL) or chemically-reinforced (Ch-R) media expansion, serum and growth factor (TGF-β and FGF-2) stimulation and hypoxia exposure ([@B119]; [@B92]; [@B25]; [@B114]; [@B138]). Importantly, our group recently showed that hPL and Ch-R formulations can effectively replace FBS to expand IFP-MSC, enhancing phenotypic and functional attributes ([@B104]).

IFP-MSC multipotentiality toward chondrogenic, osteogenic, and adipogenic lineages has been demonstrated by previous studies (reviewed in [@B164]). However, there is evidence showing that MSC differentiation capacity is strongly related to the tissue of origin. Therefore, due to the intra-articular localization of IFP tissue, and their anatomical proximity to articular cartilage, it is not surprising that IFP-MSCs exhibit strong chondrogenic differentiation capacity both *in vitro* and *in vivo* ([@B48]; [@B92]; [@B108]; [@B86]; [@B26]; [@B3], [@B1], [@B2]; [@B113]; [@B182]). Specifically, *in vitro* IFP-MSC show stronger chondrogenic differentiation capacity than adipose- derived-, BM-, and UC-MSC ([@B44]). Others however report that they possess at least comparable chondrogenic capacity to BM-MSC ([@B50]) but inferior to native chondrocytes and perivascular IFP-MSC ([@B119]; [@B176]; [@B65]; [@B78]). On this basis, studies have shown that heterogenous IFP-MSC selection for specific subpopulations may result in further enhanced chondrogenic differentiation capacity. Moreover, perivascular IFP-MSC (CD31^--^CD45^--^CD34^--^CD146^+^) generate significantly more extracellular matrix than heterogenous "crude" IFP-MSC cultures ([@B78]). Also, others reported the positive correlation of CD49c expression of donor-matched chondrocytes, BM-MSC, FP-MSC, and synovial fluid MSC with their chondrogenic capacities *in vitro* (*R* = 0.2, *p* \< 0.018, *N* = 5 samples) ([@B65]). In *in vivo* settings, freshly isolated uncultured CD44^+^ IFP-MSC seeded into a TGF-β3 ECM-derived scaffold and subcutaneously implanted in nude mice, are capable of producing a cartilage-like tissue rich of sGAG and Collagen type II ([@B1]). Therefore, the selection of specific IFP-MSC subpopulations may result in improved *in vivo* chondrogenesis.

Given their high proliferation rate and superior chondrogenic differentiation capacity, IFP-MSC may be considered a suitable candidate cell to engineer cartilaginous constructs to resurface focal defects or even an entire OA joint ([@B113]; [@B182]; [@B146]). In that regard, [@B113] showed that IFP-MSC obtained from both healthy and OA individuals and cultured on PLLA fiber membranes for 6 weeks can generate robust, flexible cartilage-like grafts of clinically relevant dimensions (≥2 cm in diameter). Of note, the authors did note that donor age variability may affect the robustness of the cultured IFP-MSCs, supporting the idea that the outcome of future IFP-MSC treatments may be substantially different in certain patient populations.

However, the main limitation of MSC-based cartilage constructs is that they progress in differentiation reaching an ultimate hypertrophic phenotype and finally undergoing endochondral ossification *in vivo* ([@B53], [@B52]; [@B154]; [@B35]; [@B56]). To overcome this limitation, co-culture of IFP-MSC with articular chondrocytes in hybrid structures result in a phenotypically stable layer of articular cartilage with reduced mineralization upon implantation in nude mice for 8 weeks ([@B130]). The same group demonstrated that self-assembled IFP-MSC on top of articular cartilage agarose gels result in higher accumulation of sGAG and therefore strongly enhance the development of articular cartilage constructs ([@B129]). Although, articular cartilage tissue engineering is a promising approach, a significant barrier is the generation of constructs with clinically relevant dimensions and in a time/cost efficient manner ready-to-use for *in vivo* implantation, especially for large compromised surfaces such as in OA. In more simplified approaches, IFP-MSC are directly injected intra-articularly solely or embedded in hydrogel-based delivery systems with and without growth factors. [@B169] showed that a single dose of intra-articularly injected IFP-MSC result in decreased cartilage degeneration, osteophyte formation, and subchondral sclerosis 20 weeks later in a rabbit OA model. Recently, [@B135] directly injected IFP-MSC embedded in matrillin-3 (an essential ECM component of cartilage) and 2% hyaluronic acid in an osteochondral defect rat model, with the reasoning that Matrilin-3 alone enhances Collagen II and aggrecan expression in chondrocytes while downregulating matrix degrading enzymes such as matrix metalloproteinase-13 (MMP-13). According to the authors, Matrillin-3, when is co-delivered with IFP-MSC, indeed resulted in greatly enhanced Collagen type II and aggrecan productions, whereas the regenerated defect site possesses similarities with native cartilage (thickness, chondrocyte clustering, and hyaline-like morphology). Overall, IFP-MSC due to their advantageous intra-articular anatomical localization and ease for harvesting along with their enhanced chondrogenic capacity may be an attractive approach for addressing articular cartilage degeneration in OA.

Our group recently reported that intra-articularly injected CD10-rich IFP-MSC reverted induced synovitis and IFP fibrosis in rats which are seen in early OA ([@B104]). Interestingly, the degree of *in vivo* efficacy is associated with the degree of expression of CD10 and degradation of Substance P, a local mediator of transmitting pain signals and regulator of neurogenic inflammation.

Synovium-Derived MSC {#S4.SS2}
--------------------

Located within the synovial intima and sub-intima lie distinct MSC populations similar to IFP-MSC, with an origin still debated ([@B109]; [@B158]). Though not populous within the tissue, these cells maintain high proliferative capacity and can differentiate into osteoblasts, adipocytes, and chondrocytes *in vitro* ([@B58]). The origin of synovium-derived MSC (sMSC) in the synovial lining is still not fully defined, with groups supporting the notion of MSC infiltrating from resident vasculature or even from the neighboring bone marrow. However, two recently reports strongly support the hypothesis of the embryonic origin of synovium at the joint interzone, by showing that single or double positive Prg4-lineage and Gdf5-lineage cells, and associated sMSC as contributors to tissue homeostasis and repair in adult life ([@B43]; [@B148]).

Besides a similar overall immunophenotype of sMSC compared with other MSC ([@B39]; [@B151]; [@B76]), CD271, a highly expressed markers in freshly isolated BM-SMC, is absent in healthy sMSC ([@B90]), yet expressed in cells isolated from OA patients ([@B76]). A topographic analysis of synovium and a full phenotypic description of sMSC are presented in our previous review ([@B103]). According to reports, sMSC show a greater proliferation rate and stronger chondrogenic capacity than BM- and adipose-derived MSC whereas they exhibit a reduced hypertrophic differentiation potential ([@B106]).

Previous studies have demonstrated that sMSC and IFP-MSC show comparable chondrogenic differentiation capacity ([@B133]). In a comparative study of three different MSC types, Mochizuki et al. indicated that sMSC and IFP-MSC have similar chondrogenic capacity between older and younger donors but higher compared to donor-matched subcutaneous fat-derived MSC ([@B133]). However, [@B177] reported that when sMSC and IFP-MSC are embedded in agarose hydrogel constructs and chondrogenic induced for 49 days *in vitro*, sMSC accumulate higher levels of sGAG and Collagen than IFP-MSC. Similarly, to IFP-MSC, sMSC expansion in hPL medium result in increased proliferation rate but lower chondrogenic capacity compared to sMSC grown in the presence of FBS ([@B137]).

In preclinical settings, [@B100] isolated sMSC from both OA and RA patients and assessed their cartilage repair capacity using a scaffold-free tissue engineering approach. Interestingly, 8 weeks post-implantation both OA or RA sMSC-treated groups showed hyaline cartilage-like repair and in general higher histological scores compared to the untreated rats. In addition, various studies using animal sMSC (rabbit-, murine-, equine-, porcine-harvested synovium) showed that sMSC groups are superior to control groups in treating full thickness chondral lesions ([@B168]). Therefore, sMSC show good reparative capacity of chondral lesions and no adverse effects after implantation *in vivo*.

MSC-Induced Immunomodulation: Focus on Macrophage Polarization {#S4.SS3}
--------------------------------------------------------------

During early phases of OA, both IFP and synovium become infiltrated by immune cells, including T cells, B cells, monocytes/macrophages, and mast cells ([@B145]; [@B159]; [@B81]; [@B87]). These infiltrates complement the local resident cells, especially macrophages, which as seen in [Figure 3](#F3){ref-type="fig"} polarize into a pro-inflammatory classical M1 phenotype (discussed above in section "Role of IFP/Synovium Resident Macrophages"). MSC exerts immunomodulatory effects, simultaneously influencing multiple immune cells through different mechanisms including cell-cell contact, soluble factors, and released extracellular vesicles (*e.g.*, exosomes). The specific effects of MSC on T cells, B cells and other immune cells have been reviewed extensively elsewhere ([@B45]; [@B72]). Herein, we emphasize on the current knowledge regarding the interactions with macrophages given their pivotal role in the initiation and progression of the disease as source of inflammatory and degradative mediators.

![Macrophages within the IFP can polarize into M1 (pro-inflammatory) or M2 (anti-inflammatory, tissue repair) variants. Both variants are associated with a multitude of unique surface markers with varying levels of expression that allow for proper identification.](fbioe-08-00860-g003){#F3}

Numerous studies have explored macrophages as potential therapeutic targets, including their pharmacological depletion from synovium and IFP and manipulation of their phenotype \[reviewed in [@B57] and [@B181]\]. Initial evidence suggests that polarization of macrophages back to an alternative anti-inflammatory M2 phenotype can be induced. M2 macrophages represent the other extreme in terms of functionality, as they play a major role in local tissue repair by secreting low levels of anti-inflammatory cytokines such as IL-10 at a much more accelerated rate compared to unpolarized "naïve" resident macrophages ([Figure 3](#F3){ref-type="fig"}) ([@B185]; [@B57]). In fact, it has been proposed that MSC can indeed promote M2 macrophage polarization *in vitro* ([@B74]). Furthermore, our group recently reported the switch of IFP macrophages from an M1 to an M2 phenotype *in vivo*, after a single intra-articular injection of a subset of BM-MSC (CD146^+^) in rats with induced synovitis and IFP fibrosis ([@B21]).

The effects of IFP-MSC in macrophage polarization are far less defined. Nevertheless, it has been described that Substance P within IFP actively participates in immune responses and inflammatory cascades (*i.e.*, neurogenic inflammation), enhancing the migration of monocytes to sites of inflammation ([@B120]; [@B161]; [@B165]). Relatedly, our group recently reported that upon exposure to a pro-inflammatory environment ([@B102]) and when manufactured under regulatory-compliant conditions ([@B104]), IFP-MSC become enriched for CD10/neprilysin, an ectopeptidase that efficiently degrades Substance P both *in vitro* and *in vivo*. The resulting CD10-rich IFP-MSC exhibit an innate ability to selectively migrate to areas of active synovitis, reverse inflammation and fibrosis of synovium and IFP. Interestingly, these effects are directly related with the level of positivity for CD10 ([@B104]). Furthermore, Substance P has been reported to induce the differentiation of pro-inflammatory macrophages into a special phagocytic M2 phenotype (M2^SP^), different from previously reported M2a and M2c subphenotypes ([@B112]).

Efforts to Translate Pre-clinical Findings Into Clinical Protocols {#S4.SS4}
------------------------------------------------------------------

MSC-based therapy to treat OA has received attention based on promising pre-clinical reports. Various cell sources have been successfully used in early-phase clinical trials, including bone marrow ([@B139]; [@B174]; [@B160]), umbilical cord ([@B123]), and adipose-derived stromal vascular fraction ([@B66]). A recent systematic review summarizing available studies testing intra-articular MSC therapy for OA and chondral defects concluded that the therapy is safe with clinical and in some cases imaging improvement ([@B126]). Synovial and IFP-derived MSC are starting to be explored clinically, yet only initial data is available.

In a pioneering case control study, a mean of 1.89 million (range, 1.2--2.3 × 10^6^) IFP-MSC with platelet-rich plasma (PRP) were intra-articularly injected in OA patients after arthroscopic debridement, and controlled against debridement + PRP alone ([@B97]). Patients were followed for up to 12--18 months, reporting no adverse effects and a significant improvement in Patient Reported Outcome Measurements (PROMs) including Lysholm score, visual analog scale (VAS), and Tegner activity were noted in the study group compared with control cohorts. However, [@B98] did note some limitations, namely that the control group was significantly different in terms of baseline radiographic and chondral lesion severity, as well as the small sample size with a focus on severe KOA patients.

The same team then in a 24--26-month follow-up study demonstrated that the significant decrease of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is directly related to the amount of injected IFP-MSC ([@B98]). The authors also found that study patients demonstrated significantly improved cartilage whole-organ MRI scores that correlated strongly with decreased pain and improved function (*R* = −0.588 and −0.0536 respectively, *p* \< 0.05, *N* = 18). Collectively, these initial results indicate the positive effect of intra-articularly injected IFP-MSC in reducing pain and improving knee function in OA patients, when compared with arthroscopic debridement and PRP alone. However, in addition to the various limitations acknowledged by the authors, the study population only included older patients with severe KOA, thus warranting further clinical investigation to determine the efficacy of the procedure as well as it's applicability to a broader clinical population.

Similarly, sMSC yielded encouraging results in treating symptomatic chondral lesions in patients. [@B155] expanded sMSC with autologous human serum and intra-articularly injected them to treat femoral condyle chondral lesions in 10 patients. For an average follow-up of 52 months, histologic analyses indicated hyaline and fibrous cartilage formation paralleled by improved Lysholm scores ([@B155]). In another study, autologous sMSC scaffold-free constructs were implanted in five patients to treat 1.5--3.0 cm^2^ chondral lesions ([@B156]). Forty-eight weeks post-implantation all patients achieved defect filling with tissue integration whereas histological analysis indicated strong cartilaginous tissue formation in all patients, with few spindle-shaped fibroblast-like cells localized only at the new-formed cartilage superficial zone. No adverse effects and significantly clinical improvements were reported at a 24-month follow-up.

These preliminary clinical studies indicated for both IFP-MSC and sMSC the overall significant improvement in cartilage repair without any complications for the patients treated. Nevertheless, the small number of patients involved and the potential confounding effect of parallel products (e.g., PRP) requires the design of prospective randomized, controlled trials to establish efficacy beyond the established safety.

Future Perspectives {#S5}
===================

The involvement of immune and inflammatory events within the synovium and IFP during early KOA has led to changes in our thinking of the disease and potential treatment approaches. Furthermore, the identification of resident and infiltrating macrophages as key modulators of those events presents a novel therapeutic target in the treatment of KOA. The ability of locally delivered IFP-MSCs to regulate synovial/IFP inflammation and fibrosis then becomes a promising therapeutic alternative to mitigate disease progression of the disease. Nevertheless, more information is required to solidly connect MSC local effects, macrophage phenotypic polarization and inflammation/fibrosis control with a durable effect limiting KOA progression.

Moreover, one critical aspect to understanding the impact of macrophages in the IFP is to dissect the molecular, cellular, and genetic identities of the heterogeneous tissue. Critically, over the past decade, numerous technologies allowing single-cell RNA sequencing (scRNA-seq) have emerged to provide unprecedented ability to examine gene expression profiles at the single cell level ([@B166]). In general, these techniques allow the deconvolution of a heterogeneous tissue into specific cell types and an examination of their abundance. Furthermore, subtle differences between cells of similar lineages can be distinguished on the basis of just a few gene expression changes. Finally, there is the ability to compare cellular profiles and gene expression across samples, conditions, or groups of individuals. While efforts are currently underway to dissect the cellular complexity of tissues throughout the body including articular cartilage during OA progression ([@B147]; [@B83]), the IFP is noticeably absent from these efforts. To our knowledge, there is no existing high throughput single cell expression profile of the IFP, either in its nascent state or following injury or in chronic disease. Given its role in the immune responses to these conditions, this remains a topic of importance moving forward in characterizing its importance.

Mechanistically, Substance P targeting and degradation by CD10-rich MSC could become a mechanism to disrupt the sustained chronic inflammation within the IFP and the transmission of nociception signals from the knee to the central nervous system. As such, the reduction of Substance P^+^ nerve fibers within IFP may possibly be related to control of KOA's most prevalent clinical presentation, joint pain.

Finally, an emerging approach results from the description of extracellular vesicles (*e.g.*, exosomes) released by MSC, and their involvement in the therapeutic activities of the cells. For instance, our previous reports indicate comparable effects between cells and their supernatant in terms of their ability to degrade Substance P. These observations may support the idea of a "cell-free" product that may recapitulate the therapeutic effects of their parental cells, with manufacturing advantages as previously described ([@B142]; [@B150]; [@B179]). In fact, the potential use of exosome-based cell-free products has already sparked multiple pre-clinical studies assessing potential clinical translation of cell-free products with encouraging results ([@B101]; [@B127]; [@B89]; [@B79]; [@B27]; [@B85]; [@B128]).

Conclusion {#S6}
==========

The knowledge accrued over the last decade regarding the IFP has led to important discoveries that elucidate its role beyond that of a vascular tissue with a biomechanical role in the anterior compartment of the knee. The proposition of the IFP and the synovium functioning as a single unit and the now recognized tight molecular crosstalk between both structures has been shown to promote resident immune cells, immune cell infiltration, and the subsequent production of articular cartilage degradative molecules associated with the propagation of various knee pathologies such as KOA. On the other hand, the presence of IFP-MSC and sMSC suggest that the IFP and synovium act as a reservoir of therapeutic cellular products engaged with repair after exposure to inflammation and subsequent injury. These MSC have also been shown to modulate macrophage phenotypic polarization in favoring immunomodulatory conditions.

The ability of local MSC to regulate synovial/IFP inflammation and fibrosis poses a promising therapeutic target to mitigate disease progression. Therefore, the IFP presents an important target for limiting joint disease progression. More information is required to better understand the connection between the local MSC population and macrophage phenotypic polarization as it relates to controlling the propagation of inflammation/fibrosis and subsequent progression of KOA.

Author Contributions {#S7}
====================

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest {#conf1}
====================

DC is a paid consultant of Lipogems USA, LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** The authors are in gratitude with the Soffer Family Foundation and the Diabetes Research Institute Foundation for their generous funding support.

[^1]: Edited by: Roberto Narcisi, Erasmus University Rotterdam, Netherlands

[^2]: Reviewed by: Cristóbal Orellana, Corporació Sanitària Parc Taulí, Spain; Guus van den Akker, Maastricht University, Netherlands

[^3]: ^†^These authors have contributed equally to this work

[^4]: ^‡^ORCID: Diego Correa [orcid.org/0000-0002-9004-4300](https://orcid.org/0000-0002-9004-4300)

[^5]: This article was submitted to Preclinical Cell and Gene Therapy, a section of the journal Frontiers in Bioengineering and Biotechnology
